152 related articles for article (PubMed ID: 10999468)
1. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
Dumas J; Hatoum-Mokdad H; Sibley R; Riedl B; Scott WJ; Monahan MK; Lowinger TB; Brennan C; Natero R; Turner T; Johnson JS; Schoenleber R; Bhargava A; Wilhelm SM; Housley TJ; Ranges GE; Shrikhande A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2051-4. PubMed ID: 10999468
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a new class of p38 kinase inhibitors.
Dumas J; Sibley R; Riedl B; Monahan MK; Lee W; Lowinger TB; Redman AM; Johnson JS; Kingery-Wood J; Scott WJ; Smith RA; Bobko M; Schoenleber R; Ranges GE; Housley TJ; Bhargava A; Wilhelm SM; Shrikhande A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2047-50. PubMed ID: 10999467
[TBL] [Abstract][Full Text] [Related]
3. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.
Redman AM; Johnson JS; Dally R; Swartz S; Wild H; Paulsen H; Caringal Y; Gunn D; Renick J; Osterhout M; Kingery-Wood J; Smith RA; Lee W; Dumas J; Wilhelm SM; Housley TJ; Bhargava A; Ranges GE; Shrikhande A; Young D; Bombara M; Scott WJ
Bioorg Med Chem Lett; 2001 Jan; 11(1):9-12. PubMed ID: 11140741
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.
Dumas J; Hatoum-Mokdad H; Sibley RN; Smith RA; Scott WJ; Khire U; Lee W; Wood J; Wolanin D; Cooley J; Bankston D; Redman AM; Schoenleber R; Caringal Y; Gunn D; Romero R; Osterhout M; Paulsen H; Housley TJ; Wilhelm SM; Pirro J; Chien DS; Ranges GE; Shrikhande A; Muzsi A; Bortolon E; Wakefield J; Gianpaolo Ostravage C; Bhargava A; Chau T
Bioorg Med Chem Lett; 2002 Jun; 12(12):1559-62. PubMed ID: 12039561
[TBL] [Abstract][Full Text] [Related]
5. N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
Wan Z; Boehm JC; Bower MJ; Kassis S; Lee JC; Zhao B; Adams JL
Bioorg Med Chem Lett; 2003 Mar; 13(6):1191-4. PubMed ID: 12643941
[TBL] [Abstract][Full Text] [Related]
6. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.
Regan J; Breitfelder S; Cirillo P; Gilmore T; Graham AG; Hickey E; Klaus B; Madwed J; Moriak M; Moss N; Pargellis C; Pav S; Proto A; Swinamer A; Tong L; Torcellini C
J Med Chem; 2002 Jul; 45(14):2994-3008. PubMed ID: 12086485
[TBL] [Abstract][Full Text] [Related]
7. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.
Cirillo PF; Pargellis C; Regan J
Curr Top Med Chem; 2002 Sep; 2(9):1021-35. PubMed ID: 12171569
[TBL] [Abstract][Full Text] [Related]
8. A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors.
Schlapbach A; Heng R; Di Padova F
Bioorg Med Chem Lett; 2004 Jan; 14(2):357-60. PubMed ID: 14698158
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
Graneto MJ; Kurumbail RG; Vazquez ML; Shieh HS; Pawlitz JL; Williams JM; Stallings WC; Geng L; Naraian AS; Koszyk FJ; Stealey MA; Xu XD; Weier RM; Hanson GJ; Mourey RJ; Compton RP; Mnich SJ; Anderson GD; Monahan JB; Devraj R
J Med Chem; 2007 Nov; 50(23):5712-9. PubMed ID: 17948975
[TBL] [Abstract][Full Text] [Related]
10. Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.
Khire UR; Bankston D; Barbosa J; Brittelli DR; Caringal Y; Carlson R; Dumas J; Gane T; Heald SL; Hibner B; Johnson JS; Katz ME; Kennure N; Kingery-Wood J; Lee W; Liu XG; Lowinger TB; McAlexander I; Monahan MK; Natero R; Renick J; Riedl B; Rong H; Sibley RN; Smith RA; Wolanin D
Bioorg Med Chem Lett; 2004 Feb; 14(3):783-6. PubMed ID: 14741289
[TBL] [Abstract][Full Text] [Related]
11. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.
Mclay LM; Halley F; Souness JE; McKenna J; Benning V; Birrell M; Burton B; Belvisi M; Collis A; Constan A; Foster M; Hele D; Jayyosi Z; Kelley M; Maslen C; Miller G; Ouldelhkim MC; Page K; Phipps S; Pollock K; Porter B; Ratcliffe AJ; Redford EJ; Webber S; Slater B; Thybaud V; Wilsher N
Bioorg Med Chem; 2001 Feb; 9(2):537-54. PubMed ID: 11249145
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors.
Kulkarni RG; Laufer S; Mangannavar C; Garlapati A
Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase inhibitors from the urea class.
Dumas J
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):718-27. PubMed ID: 12630292
[TBL] [Abstract][Full Text] [Related]
15. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.
Mavunkel BJ; Chakravarty S; Perumattam JJ; Luedtke GR; Liang X; Lim D; Xu YJ; Laney M; Liu DY; Schreiner GF; Lewicki JA; Dugar S
Bioorg Med Chem Lett; 2003 Sep; 13(18):3087-90. PubMed ID: 12941340
[TBL] [Abstract][Full Text] [Related]
16. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.
Thompson AM; Connolly CJ; Hamby JM; Boushelle S; Hartl BG; Amar AM; Kraker AJ; Driscoll DL; Steinkampf RW; Patmore SJ; Vincent PW; Roberts BJ; Elliott WL; Klohs W; Leopold WR; Showalter HD; Denny WA
J Med Chem; 2000 Nov; 43(22):4200-11. PubMed ID: 11063616
[TBL] [Abstract][Full Text] [Related]
17. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
[TBL] [Abstract][Full Text] [Related]
18. Pyridinylimidazole based p38 MAP kinase inhibitors.
Jackson PF; Bullington JL
Curr Top Med Chem; 2002 Sep; 2(9):1011-20. PubMed ID: 12171568
[TBL] [Abstract][Full Text] [Related]
19. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
[TBL] [Abstract][Full Text] [Related]
20. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.
Wang GT; Li G; Mantei RA; Chen Z; Kovar P; Gu W; Xiao Z; Zhang H; Sham HL; Sowin T; Rosenberg SH; Lin NH
J Med Chem; 2005 May; 48(9):3118-21. PubMed ID: 15857116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
